Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracytes Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today results from the independent OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) trial, led by University College London (UCL). The results, which will be presented at the...